Here are 1-3 brief analogies for Prenetics Global (PRE):

• Like 23andMe, but focused on medical diagnostics and early disease detection.
• A genomics-driven Quest Diagnostics.

• Circle Health Screening: Provides comprehensive at-home or clinic-based genetic and blood tests offering personalized health insights and risk assessments for various conditions.
• ACT Genomics Oncology Solutions: Delivers genomic profiling services for cancer patients to guide treatment selection, monitor disease progression, and facilitate early detection.
• ColoClear: Offers a non-invasive, stool-based DNA test for the early detection and screening of colorectal cancer.
• Insight Pharmacogenomics: Provides genetic testing to predict an individual's response to specific medications, aiding in personalized drug selection and dosing.

Prenetics Global (symbol: PRE) serves a diverse customer base across both Business-to-Business (B2B) and Direct-to-Consumer (DTC) segments. According to their recent public filings, no single customer accounted for 10% or more of their total revenue in recent fiscal years, indicating a broad and diversified customer portfolio rather than reliance on a few major named customers.

However, their customer base can be broadly categorized into the following groups:

B2B Customers (Companies and Institutions):

Prenetics Global provides diagnostic and health-screening services to various organizations. While specific names are not disclosed as major customers, the categories of companies they serve include:

• Healthcare Providers, Institutions, and Governments: This category includes hospitals, clinics, diagnostic laboratories, and government bodies (e.g., health departments, airport authorities). They historically provided large-scale COVID-19 testing solutions to governmental entities and public transport hubs, and continue to offer clinical diagnostic services.
• Corporations and Enterprises: Businesses that contract Prenetics for corporate wellness programs, employee health screening, or previously, large-scale COVID-19 testing for their workforce. These services help companies manage employee health and well-being.

B2C Customers (Individuals):

Prenetics also directly serves individuals through its direct-to-consumer brand:

• Individual Consumers: Customers who purchase genetic testing kits (e.g., through their CircleDNA brand) for personalized health insights, dietary recommendations, fitness predispositions, ancestry information, and other wellness-related genetic data directly from the company.

• Illumina, Inc. (ILMN)
• Thermo Fisher Scientific Inc. (TMO)

Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Prior to Prenetics, Mr. Yeung founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. He then served as CEO of Groupon East Asia. His entrepreneurial journey began at age 25, franchising the Hong Kong dessert chain “Hui Lau Shan” into the USA, and later venturing into hospitality furniture. Mr. Yeung was also a Founding Partner at SXE Ventures, where he led multiple investments in genetic testing companies and in Honey Science, which was acquired by PayPal for US$4 billion in 2019.

Stephen Lo has served as the Chief Financial Officer of Prenetics since 2018, overseeing financial operations, corporate accounting and reporting, treasury, financial and tax planning and analysis, and investor relations. Before joining Prenetics, Mr. Lo was in the Asia Pacific Investment Banking team of Citigroup from 2014 to 2018, working on initial public offering transactions, placements, debt issuances, and cross-border mergers and acquisitions. From 2007 to 2011, he was an auditor with Ernst & Young. Mr. Lo joined Prenetics when it was a startup, taking a significant salary cut and career risk, and was instrumental in building the finance team.

Dr. Lawrence Tzang is the Co-Founder of Prenetics and has served as its Chief Scientific Officer and a director since its founding in 2014. He is responsible for overseeing the development, evaluation, and implementation of new testing products and services, as well as the supervision of laboratory setup and operation and the governance of medical laboratory accreditation.

Joel Neoh serves as the Chief Consumer Officer of Prenetics.

Dr. Senthil Sundaram is the Chief Clinical Officer of Prenetics. He is recognized for his experience as a physician-scientist, having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants using next-generation sequencing technologies and has published research articles in prominent journals such as Neurology, Annals of Neurology, and Cerebral Cortex.

The key risks to Prenetics Global (PRE) are:

1. Unprofitability and Sustained Financial Performance: Prenetics Global has reported a negative net margin, indicating that the company is currently unprofitable. For example, it had a negative net margin of 61.3% as of a recent reporting period, and analysts expect negative earnings per share for the current fiscal year. This ongoing unprofitability poses a significant risk to the company's financial stability and long-term sustainability.
2. Regulatory and Compliance Risks in Health Sciences: Operating in the health sciences sector, particularly with direct-to-consumer DNA tests and precision oncology diagnostics, exposes Prenetics Global to extensive and evolving regulatory scrutiny. Changes in regulations, the need for continuous compliance, and the lengthy and costly processes for obtaining and maintaining product clearances (such as FDA clearance for diagnostic tools like ACTOnco) can impact product development, market access, and operational costs.
3. Volatility and Exposure from Bitcoin Treasury: Prenetics Global has established a Bitcoin treasury with a substantial initial purchase, pioneering the intersection of healthcare innovation and digital asset adoption. While potentially innovative, this exposes the company to the inherent volatility and risks associated with cryptocurrency markets, which can experience rapid and significant price fluctuations, impacting the company's financial position.

Prenetics Global (PRE) operates primarily in the consumer health and wellness sector, with its main products and services including health and longevity supplements under the IM8 brand and direct-to-consumer genetic testing through CircleDNA.

The addressable market sizes for these main products are:

• IM8 (Anti-Aging Supplements): The global market size for anti-aging supplements was valued at approximately $4.47 billion in 2024. This market is projected to grow to about $6.99 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 7.89% between 2025 and 2030.
• CircleDNA (Genetic Testing): The global genetic testing market was valued at an estimated $18.6 billion in 2023. It is projected to reach approximately $52.3 billion by 2032, with a CAGR of 12.3% from 2024 to 2032. Another estimate places the global genetic testing market size at $24.45 billion in 2025, with a forecast to grow to about $71.09 billion by 2035, exhibiting a CAGR of 11.26% from 2026 to 2035.

The expected drivers of future revenue growth for Prenetics Global (PRE) over the next 2-3 years are primarily centered around its strategic pivot to become a pure-play consumer health leader, with a strong focus on its IM8 brand.

1. Explosive Growth and Global Expansion of IM8: The IM8 premium consumer health brand, co-founded with David Beckham, is the company's primary revenue growth driver. IM8 achieved a $120 million annualized revenue run rate in its first year (2025) and is projected to generate between $180 million and $200 million in revenue for the full year 2026, representing nearly 300% year-over-year growth. The company aims for IM8 to reach a $300 million annual recurring revenue by the end of 2026, driven by continued international expansion.
2. Launch of New Products within the IM8 Ecosystem: Prenetics plans to diversify its portfolio and accelerate growth by introducing two new products in Q4 2026. These products are expected to target very large addressable markets under the IM8 brand.
3. Enhanced Brand Activation and Marketing Initiatives: Continued investment in marketing and enhanced brand activation are crucial for driving IM8's growth. These initiatives will span across multiple sports and wellness verticals to further scale the brand globally.
4. Strategic Focus on High-Margin Consumer Health: The company has undergone a significant transformation by divesting non-core and lower-margin assets, such as ACT Genomics and Europa. This strategic shift allows Prenetics to concentrate its resources and capital on its high-growth, high-margin consumer health businesses, thereby enhancing its overall revenue growth and profitability profile.

Share Repurchases

• Prenetics Global's Board of Directors authorized a share repurchase program of up to $40 million over a 12-month period, announced on March 6, 2026.
• Executive leadership made open market purchases totaling approximately $2.75 million across two consecutive post-earnings trading windows in February and November 2025.

Share Issuance

• The company completed a $44 million equity offering on October 28, 2025, which attracted high-profile strategic investors.
• Prenetics Global became publicly traded on Nasdaq on May 18, 2022, through a merger with Artisan Acquisition Corp., which provided up to US$459 million in cash proceeds.

Inbound Investments

• Upon going public on May 18, 2022, through a SPAC merger, Prenetics Global received up to US$459 million in cash proceeds, including a fully committed PIPE and forward purchase agreements of US$120 million from various investors such as Aspex, PAG, Lippo, Dragonstone, and Xen Capital.
• A $44 million equity offering, which closed on October 28, 2025, attracted high-quality strategic investors into the company.

Outbound Investments

• Prenetics Global acquired Europa Sports Partners and its subsidiary, Hubmatrix, a global e-commerce and retail logistics provider, financed with cash from its balance sheet.
• In October 2025, the company acquired 100 Bitcoin, bringing its total holdings to 378 BTC (valued at approximately $46 million at the time), though it ceased further Bitcoin purchases in December 2025 to focus on its IM8 brand.
• During 2025 and early 2026, the company completed several strategic divestitures, including the sale of its 35% equity interest in Insighta to Tencent for $70 million in cash, the sale of ACT Genomics for up to $72 million in cash, and the sale of the Europa distribution business for up to $13 million in stock consideration.